Immune Modulating Prodrugs (IMPs)
The Key to Nammisome Success
All active agents are clinically validated molecules
Enables efficient and stable incorporation into Nammisomes
Maintains immune modulating agents in an Inactive state until released by intracellular esterases
Provides IP and FTO
Mechanisms of validated prodrugs:
Programmed cell death protein 1 (PD-1) Antagonist
Toll Receptor (TLR)1/2 Agonist
Toll Receptor (TLR)4 Agonist
Toll Receptor (TLR)7 Agonist
Indoleamine 2,3-dioxygenase-1 (IDO-1) Antagonist
Adenosine 2A Receptor (A2AR) antagonist
Tumor Growth Factor Beta (TGF-β) inhibitor
Design of a Nammisome
Nammisomes: Designed to Tackle the Key Challenges of Immunotherapies
Enables incorporation of multiple immunotherapy mechanisms of action into a single drug product , thereby enhancing efficacy and reducing development time/costs.
Prodrug design and incorporation into Nammisome maintains immunotherapy in an inactive state in circulation and prevents ‘leaching’ of the agents from the nanoparticles, enhancing pharmacokinetics and preventing systemic immune activation.
Physicochemical properties of Nammisomes are designed to allow them to avoid uptake by cells in circulation, while taking advantage of the abnormal and leaky vasculature of tumors to escape and accumulate within tumors.